NASDAQ:KZIA Novogen (KZIA) Stock Price, News & Analysis $8.34 +0.16 (+1.96%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$9.80 +1.46 (+17.51%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Novogen Stock (NASDAQ:KZIA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novogen alerts:Sign Up Key Stats Today's Range$7.85▼$8.6650-Day Range$3.56▼$11.4352-Week Range$2.86▼$39.05Volume26,112 shsAverage Volume687,823 shsMarket Capitalization$8.42 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingStrong Buy Company Overview Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. Read More Novogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreKZIA MarketRank™: Novogen scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingNovogen has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNovogen has only been the subject of 2 research reports in the past 90 days.Read more about Novogen's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.48% of the outstanding shares of Novogen have been sold short.Short Interest Ratio / Days to CoverNovogen has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novogen has recently increased by 151.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovogen does not currently pay a dividend.Dividend GrowthNovogen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.48% of the outstanding shares of Novogen have been sold short.Short Interest Ratio / Days to CoverNovogen has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novogen has recently increased by 151.11%, indicating that investor sentiment is decreasing significantly. News and Social Media0.9 / 5News Sentiment-0.45 News SentimentNovogen has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Novogen this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for KZIA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Novogen is held by insiders.Percentage Held by InstitutionsOnly 30.89% of the stock of Novogen is held by institutions.Read more about Novogen's insider trading history. Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novogen and its competitors with MarketBeat's FREE daily newsletter. Email Address KZIA Stock News HeadlinesNovogen (NASDAQ:KZIA) Lowered to Sell Rating by Wall Street ZenAugust 3 at 2:35 AM | americanbankingnews.comKazia Therapeutics Announces $2 Million Private Placement at Premium to MarketAugust 1, 2025 | prnewswire.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant. | The Oxford Club (Ad)Novogen (NASDAQ:KZIA) Rating Increased to Hold at Wall Street ZenJuly 26, 2025 | americanbankingnews.comKazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b TrialJuly 9, 2025 | prnewswire.comKazia Therapeutics Shares Jump After Data Shows Lead Asset Could Treat Breast CancerJune 11, 2025 | marketwatch.comKazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)June 11, 2025 | prnewswire.comKazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast CancerJune 5, 2025 | prnewswire.comSee More Headlines KZIA Stock Analysis - Frequently Asked Questions How have KZIA shares performed this year? Novogen's stock was trading at $8.85 on January 1st, 2025. Since then, KZIA shares have decreased by 5.8% and is now trading at $8.34. When did Novogen's stock split? Shares of Novogen reverse split before market open on Monday, October 28th 2024.The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Novogen? Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novogen investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Today8/05/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KZIA Previous SymbolASX:KZA CIK1075880 Webwww.kaziatherapeutics.com Phone(129) 472-4101Fax61-2-9476-0388Employees12Year FoundedN/APrice Target and Rating Average Price Target for Novogen$14.00 High Price Target$15.00 Low Price Target$13.00 Potential Upside/Downside+67.9%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick RatioN/A Sales & Book Value Annual Sales$1.51 million Price / Sales5.58 Cash FlowN/A Price / Cash FlowN/A Book Value($9.87) per share Price / Book-0.84Miscellaneous Outstanding Shares1,010,000Free Float997,000Market Cap$8.42 million OptionableOptionable Beta2.64 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:KZIA) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novogen Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Novogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.